SCYNEXIS, Inc.(SCYX)Earnings, Financials & Key Ratios
SCYX•NASDAQ
$0.98
$43M mkt cap·Price updated May 6, 2026
AboutSCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Show more
- Revenue$21M+449.9%
- EBITDA-$16M+54.6%
- Net Income-$9M+59.6%
- EPS (Diluted)-0.17+61.4%
- EBITDA Margin-78.03%+91.7%
- Operating Margin-78.03%+92.1%
- Net Margin-41.79%+92.6%
- ROE-16.48%+50.4%
- ROIC-28.17%+44.7%
- Debt/Equity0.04-85.1%
- Interest Coverage-33.14-128.1%
SCYX Key Insights
SCYNEXIS, Inc. (SCYX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 42.1%
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SCYX Price & Volume
SCYNEXIS, Inc. (SCYX) stock price & volume — 10-year historical chart
Loading chart...
SCYX Growth Metrics
SCYNEXIS, Inc. (SCYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years55.02%
5 Years-
3 Years59.35%
TTM449.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM59.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM70.17%
Return on Capital
10 Years-52.7%
5 Years-30.52%
3 Years3.78%
Last Year-26.83%
SCYX Peer Comparison
SCYNEXIS, Inc. (SCYX) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 CDTX | 6.96B | 221.38 | -8.28 | -94.52% | -43.74% | 0.02 | ||
 ATXS | 718.13M | 12.58 | -7.49 | -175.68% | -53.17% | 0.02 | ||
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 MRK | 280.48B | 113.56 | 15.60 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare SCYX vs Peers
SCYNEXIS, Inc. (SCYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SCYX Income Statement
SCYNEXIS, Inc. (SCYX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 257K | 257K | 121K | 0 | 13.16M | 5.09M | 140.14M | 3.75M | 20.6M |
| Revenue Growth % | 0% | 0% | -52.92% | -100% | - | -61.32% | 2652.72% | -97.33% | 449.95% |
| Cost of Goods Sold | 0 | 0 | 0 | 303K | 312K | 628K | 15.62M | 0 | 0 |
| COGS % of Revenue | - | - | - | - | 2.37% | 12.34% | 11.15% | - | - |
| Gross Profit | 257K▲ 0% | 257K▲ 0.0% | 121K▼ 52.9% | -303K▼ 350.4% | 12.85M▲ 4341.3% | 4.46M▼ 65.3% | 124.52M▲ 2690.0% | 3.75M▼ 97.0% | 0▼ 100.0% |
| Gross Margin % | 100% | 100% | 100% | - | 97.63% | 87.66% | 88.85% | 100% | - |
| Gross Profit Growth % | 0% | 0% | -52.92% | -350.41% | 4341.25% | -65.27% | 2689.98% | -96.99% | -100% |
| Operating Expenses | 26.58M | 30.24M | 49.04M | 50.85M | 73.69M | 90.22M | 51.85M | 40.86M | 36.67M |
| OpEx % of Revenue | 10341.25% | 11766.54% | 40530.58% | - | 559.82% | 1772.15% | 37% | 1090.84% | 178.03% |
| Selling, General & Admin | 8.25M | 8.68M | 10.65M | 14.32M | 49.92M | 62.96M | 20.92M | 14.46M | 14.39M |
| SG&A % of Revenue | 3210.51% | 3377.43% | 8800% | - | 379.21% | 1236.71% | 14.93% | 385.96% | 69.88% |
| Research & Development | 18.33M | 21.56M | 38.39M | 36.52M | 23.77M | 27.26M | 30.93M | 26.41M | 22.28M |
| R&D % of Revenue | 7130.74% | 8389.11% | 31730.58% | - | 180.6% | 535.44% | 22.07% | 704.89% | 108.15% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.32M▲ 0% | -29.98M▼ 13.9% | -48.92M▼ 63.2% | -51.15M▼ 4.6% | -60.84M▼ 18.9% | -85.76M▼ 41.0% | 72.67M▲ 184.7% | -37.12M▼ 151.1% | -16.07M▲ 56.7% |
| Operating Margin % | -10241.25% | -11666.54% | -40430.58% | - | -462.19% | -1684.48% | 51.85% | -990.84% | -78.03% |
| Operating Income Growth % | 5.38% | -13.92% | -63.16% | -4.55% | -18.94% | -40.96% | 184.74% | -151.08% | 56.69% |
| EBITDA | -26.28M | -29.93M | -48.64M | -50.85M | -60.46M | -84.94M | 73.25M | -35.39M | -16.07M |
| EBITDA Margin % | -10225.29% | -11645.91% | -40195.04% | - | -459.31% | -1668.51% | 52.27% | -944.77% | -78.03% |
| EBITDA Growth % | 5.44% | -13.89% | -62.5% | -4.54% | -18.91% | -40.5% | 186.23% | -148.32% | 54.58% |
| D&A (Non-Cash Add-back) | 41K | 53K | 285K | 303K | 379K | 813K | 580K | 1.73M | 0 |
| EBIT | -23.2M | -17.15M | -51.55M | -55.95M | -33.29M | -60.72M | 70.31M | -20.31M | -16.07M |
| Net Interest Income | -1.47M | -1.09M | -1.35M | -992K | -3.94M | -5.37M | -2.17M | 1.74M | 1.69M |
| Interest Income | 386K | 967K | 805K | 189K | 24K | 1.42M | 3.95M | 4.29M | 2.18M |
| Interest Expense | 1.85M | 2.05M | 2.16M | 1.18M | 3.96M | 6.79M | 6.12M | 2.55M | 485K |
| Other Income/Expense | 1.26M | 10.78M | -4.79M | -7.18M | 24.88M | 18.25M | -5.49M | 15.98M | 7.46M |
| Pretax Income | -25.06M▲ 0% | -19.2M▲ 23.4% | -53.71M▼ 179.7% | -58.33M▼ 8.6% | -35.95M▲ 38.4% | -67.51M▼ 87.8% | 67.18M▲ 199.5% | -21.14M▼ 131.5% | -8.61M▲ 59.3% |
| Pretax Margin % | -9750.97% | -7472.37% | -44388.43% | - | -273.14% | -1326.05% | 47.94% | -564.26% | -41.79% |
| Income Tax | 0 | -6.74M | 0 | -3.15M | -3.09M | -4.7M | 138K | 151K | 0 |
| Effective Tax Rate % | 0% | 35.08% | 0% | 5.4% | 8.59% | 6.96% | 0.21% | -0.71% | 0% |
| Net Income | -25.06M▲ 0% | -12.47M▲ 50.2% | -53.71M▼ 330.8% | -55.19M▼ 2.7% | -32.87M▲ 40.4% | -62.81M▼ 91.1% | 67.04M▲ 206.7% | -21.29M▼ 131.8% | -8.61M▲ 59.6% |
| Net Margin % | -9750.97% | -4851.36% | -44388.43% | - | -249.68% | -1233.73% | 47.84% | -568.29% | -41.79% |
| Net Income Growth % | 16.44% | 50.25% | -330.78% | -2.75% | 40.44% | -91.11% | 206.74% | -131.75% | 59.56% |
| Net Income (Continuing) | -25.06M | -12.47M | -53.71M | -55.19M | -32.87M | -62.81M | 67.04M | -21.29M | -8.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -9.37▲ 0% | -2.84▲ 69.7% | -9.85▼ 246.8% | -5.15▲ 47.7% | -1.25▲ 75.7% | -1.47▼ 17.6% | 1.39▲ 194.6% | -0.44▼ 131.7% | -0.17▲ 61.4% |
| EPS Growth % | 40.51% | 69.69% | -246.83% | 47.72% | 75.73% | -17.6% | 194.56% | -131.65% | 61.36% |
| EPS (Basic) | -9.37 | -2.84 | -9.85 | -5.15 | -1.25 | -1.47 | 1.40 | -0.44 | -0.17 |
| Diluted Shares Outstanding | 2.67M | 4.39M | 5.61M | 10.72M | 26.38M | 42.61M | 48.39M | 48.51M | 49.93M |
| Basic Shares Outstanding | 2.67M | 4.39M | 5.61M | 10.72M | 26.38M | 42.61M | 47.85M | 48.51M | 49.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SCYX Balance Sheet
SCYNEXIS, Inc. (SCYX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 44.96M | 51.46M | 52.4M | 98.21M | 109.38M | 79.06M | 102.12M | 72.18M | 40.37M |
| Cash & Short-Term Investments | 43.89M | 44.16M | 48.41M | 93.04M | 104.48M | 73.5M | 74.36M | 59.3M | 21.26M |
| Cash Only | 11.47M | 11.44M | 41.92M | 93.04M | 104.48M | 45.81M | 34.05M | 16.05M | 21.26M |
| Short-Term Investments | 32.42M | 32.72M | 6.49M | 0 | 0 | 27.69M | 40.31M | 43.25M | 0 |
| Accounts Receivable | 251K | 6.73M | 0 | 2.88M | 861K | 2.1M | 21.83M | 10.26M | 0 |
| Days Sales Outstanding | 356.48 | 9.56K | - | - | 23.87 | 150.63 | 56.85 | 999.9 | - |
| Inventory | 725K | 520K | 0 | 0 | 463K | 899K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 541.65 | 522.51 | - | - | - |
| Other Current Assets | 91K | 109K | 674K | 373K | 4K | 117K | 5.29M | 1.67M | 19.11M |
| Total Non-Current Assets | 890K | 1.71M | 4.75M | 4.33M | 10.46M | 8.75M | 26.3M | 18.46M | 18.65M |
| Property, Plant & Equipment | 4K | 516K | 3.6M | 3.3M | 2.91M | 2.59M | 2.36M | 2.09M | 1.76M |
| Fixed Asset Turnover | 64.25x | 0.50x | 0.03x | - | 4.52x | 1.96x | 59.28x | 1.79x | 11.68x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 1.06M | 408K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 273K | 0 | 0 | 218K | 163K | 23.59M | 15.85M | 16.25M |
| Other Non-Current Assets | 886K | 918K | 1.16M | 1.03M | 6.49M | 5.75M | 338K | 526K | 642K |
| Total Assets | 45.85M▲ 0% | 53.17M▲ 16.0% | 57.15M▲ 7.5% | 102.54M▲ 79.4% | 119.84M▲ 16.9% | 87.81M▼ 26.7% | 128.41M▲ 46.2% | 90.64M▼ 29.4% | 59.03M▼ 34.9% |
| Asset Turnover | 0.01x | 0.00x | 0.00x | - | 0.11x | 0.06x | 1.09x | 0.04x | 0.35x |
| Asset Growth % | -23.32% | 15.97% | 7.49% | 79.41% | 16.87% | -26.73% | 46.24% | -29.41% | -34.88% |
| Total Current Liabilities | 10.14M | 5.88M | 11.01M | 26.4M | 13.62M | 17.62M | 16.3M | 24.1M | 5.73M |
| Accounts Payable | 3.83M | 3.65M | 7.18M | 4.64M | 7.85M | 5.94M | 7.15M | 4.57M | 2.23M |
| Days Payables Outstanding | - | - | - | 5.59K | 9.18K | 3.45K | 167.01 | - | - |
| Short-Term Debt | 4.35M | 0 | 0 | 0 | 70K | 0 | 0 | 13.69M | 483K |
| Deferred Revenue (Current) | 257K | 121K | 0 | 0 | 0 | 0 | 1.19M | 1.64M | 235K |
| Other Current Liabilities | 913K | 885K | 1.8M | 19.75M | 3.62M | 5.77M | 1.83M | 1.76M | 2.79M |
| Current Ratio | 4.43x | 8.76x | 4.76x | 3.72x | 8.03x | 4.49x | 6.26x | 3.00x | 7.04x |
| Quick Ratio | 4.36x | 8.67x | 4.76x | 3.72x | 8.00x | 4.44x | 6.26x | 3.00x | 7.04x |
| Cash Conversion Cycle | - | - | - | - | -8.62K | -2.78K | - | - | - |
| Total Non-Current Liabilities | 14.3M | 16.07M | 33.24M | 53.38M | 64.96M | 66.96M | 39.15M | 11.47M | 3.92M |
| Long-Term Debt | 10.3M | 15.08M | 11.52M | 16.52M | 40.35M | 45.39M | 12.16M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 3.33M | 3.27M | 3.2M | 2.92M | 2.58M | 2.17M | 1.69M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.87M | 986K | 18.4M | 33.59M | 21.41M | 18.64M | 21.68M | 8M | 2.23M |
| Total Liabilities | 24.44M | 21.95M | 44.26M | 79.78M | 78.58M | 84.58M | 55.45M | 35.57M | 9.65M |
| Total Debt | 14.65M | 15.08M | 14.88M | 19.84M | 43.63M | 48.6M | 15.08M | 16.27M | 2.17M |
| Net Debt | 3.18M | 3.64M | -27.04M | -73.2M | -60.86M | 2.78M | -18.97M | 219K | -19.08M |
| Debt / Equity | 0.68x | 0.48x | 1.15x | 0.87x | 1.06x | 15.03x | 0.21x | 0.30x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | 0.21x | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | -0.26x | - | - |
| Interest Coverage | -14.19x | -14.60x | -22.68x | -43.31x | -15.35x | -12.64x | 11.87x | -14.53x | -33.14x |
| Total Equity | 21.41M▲ 0% | 31.23M▲ 45.8% | 12.89M▼ 58.7% | 22.76M▲ 76.5% | 41.26M▲ 81.3% | 3.23M▼ 92.2% | 72.96M▲ 2156.8% | 55.08M▼ 24.5% | 49.38M▼ 10.4% |
| Equity Growth % | -38.51% | 45.84% | -58.7% | 76.49% | 81.29% | -92.16% | 2156.79% | -24.51% | -10.35% |
| Book Value per Share | 8.00 | 7.12 | 2.30 | 2.12 | 1.56 | 0.08 | 1.51 | 1.14 | 0.99 |
| Total Shareholders' Equity | 21.41M | 31.23M | 12.89M | 22.76M | 41.26M | 3.23M | 72.96M | 55.08M | 49.38M |
| Common Stock | 29K | 48K | 10K | 20K | 32K | 36K | 40K | 41K | 46K |
| Retained Earnings | -205.25M | -217.72M | -271.43M | -326.61M | -359.48M | -422.29M | -355.25M | -376.54M | -385.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SCYX Cash Flow Statement
SCYNEXIS, Inc. (SCYX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.56M | -28.32M | -38.12M | -49.35M | -54.56M | -79.88M | 60.16M | -24.01M | -5.28M |
| Operating CF Margin % | -9554.86% | -11020.62% | -31503.31% | - | -414.5% | -1569.1% | 42.93% | -640.92% | -25.64% |
| Operating CF Growth % | 16.34% | -15.34% | -34.59% | -29.47% | -10.55% | -46.41% | 175.31% | -139.91% | 78% |
| Net Income | -25.06M | -12.47M | -53.71M | -55.19M | -32.87M | -62.81M | 67.04M | -21.29M | -8.61M |
| Depreciation & Amortization | 41K | 53K | 111K | 111K | 379K | 606K | 580K | 1.73M | 312K |
| Stock-Based Compensation | 1.66M | 1.82M | 1.83M | 2.22M | 2.09M | 3.69M | 2.62M | 3.35M | 2.85M |
| Deferred Taxes | -2.6M | -11.75M | 3.96M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 375K | 424K | 1.34M | 6.72M | -27.31M | -22.13M | 20.56M | -15.08M | -5.92M |
| Working Capital Changes | 1.03M | -6.4M | 8.35M | -3.22M | 3.15M | 764K | -30.64M | 7.28M | 6.08M |
| Change in Receivables | 0 | 0 | 0 | 0 | -861K | -1.24M | -19.73M | 11.56M | 10.26M |
| Change in Inventory | 0 | 0 | 0 | 0 | -5.29M | -436K | -8.85M | 0 | 0 |
| Change in Payables | 2.08M | 223K | 5.21M | -2.6M | 2.76M | -1.48M | 1.17M | -2.65M | -2.23M |
| Cash from Investing | -9.62M | -803K | 26.24M | 6.47M | -1.17M | -27.39M | -34.88M | 6.15M | 24.31M |
| Capital Expenditures | -2K | -565K | 0 | -4K | -1.17M | -9K | 0 | 0 | 0 |
| CapEx % of Revenue | 0.78% | 219.84% | - | - | 8.9% | 0.18% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -9.62M | -238K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 9.99M | 29.42M | 42.3M | 94M | 67.12M | 48.6M | -36.72M | -139K | -14.17M |
| Debt Issued (Net) | 0 | 0 | 27K | 9.51M | 30M | 5M | -36.65M | 0 | -14M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 18K | -139K | -170K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -208K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -298K | -2.23M | -1.25M | -5.85M | -1.44M | -26K | -93K | 0 | 0 |
| Net Change in Cash | -24.19M▲ 0% | 298K▲ 101.2% | 30.43M▲ 10110.1% | 51.12M▲ 68.0% | 11.39M▼ 77.7% | -58.67M▼ 615.2% | -11.44M▲ 80.5% | -18M▼ 57.3% | 4.85M▲ 127.0% |
| Free Cash Flow | -24.56M▲ 0% | -28.89M▼ 17.6% | -38.12M▼ 32.0% | -49.36M▼ 29.5% | -55.73M▼ 12.9% | -79.89M▼ 43.4% | 60.16M▲ 175.3% | -24.01M▼ 139.9% | -5.28M▲ 78.0% |
| FCF Margin % | -9555.64% | -11240.47% | -31503.31% | - | -423.4% | -1569.28% | 42.93% | -640.92% | -25.64% |
| FCF Growth % | 16.41% | -17.63% | -31.95% | -29.48% | -12.91% | -43.35% | 175.3% | -139.91% | 78% |
| FCF per Share | -9.18 | -6.58 | -6.80 | -4.60 | -2.11 | -1.87 | 1.24 | -0.49 | -0.11 |
| FCF Conversion (FCF/Net Income) | 0.98x | 2.27x | 0.71x | 0.89x | 1.66x | 1.27x | 0.90x | 1.13x | 0.61x |
| Interest Paid | 0 | 0 | 0 | 1.09M | 2.25M | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SCYX Key Ratios
SCYNEXIS, Inc. (SCYX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -78.13% | -89.14% | -47.38% | -243.47% | -309.57% | -102.68% | -282.34% | 175.97% | -33.25% | -16.48% |
| Return on Invested Capital (ROIC) | -497.98% | -103.87% | -75.64% | -354.04% | - | - | -1069.11% | 181.65% | -50.94% | -28.17% |
| Gross Margin | 100% | 100% | 100% | 100% | - | 97.63% | 87.66% | 88.85% | 100% | - |
| Net Margin | -11668.87% | -9750.97% | -4851.36% | -44388.43% | - | -249.68% | -1233.73% | 47.84% | -568.29% | -41.79% |
| Debt / Equity | 0.41x | 0.68x | 0.48x | 1.15x | 0.87x | 1.06x | 15.03x | 0.21x | 0.30x | 0.04x |
| Interest Coverage | -61.68x | -14.19x | -14.60x | -22.68x | -43.31x | -15.35x | -12.64x | 11.87x | -14.53x | -33.14x |
| FCF Conversion | 0.98x | 0.98x | 2.27x | 0.71x | 0.89x | 1.66x | 1.27x | 0.90x | 1.13x | 0.61x |
| Revenue Growth | 0% | 0% | 0% | -52.92% | -100% | - | -61.32% | 2652.72% | -97.33% | 449.95% |
SCYX Frequently Asked Questions
SCYNEXIS, Inc. (SCYX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SCYNEXIS, Inc. (SCYX) reported $20.6M in revenue for fiscal year 2025. This represents a 22% increase from $16.8M in 2012.
SCYNEXIS, Inc. (SCYX) grew revenue by 449.9% over the past year. This is strong growth.
SCYNEXIS, Inc. (SCYX) reported a net loss of $8.6M for fiscal year 2025.
Dividend & Returns
SCYNEXIS, Inc. (SCYX) has a return on equity (ROE) of -16.5%. Negative ROE indicates the company is unprofitable.
SCYNEXIS, Inc. (SCYX) had negative free cash flow of $5.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More SCYX
SCYNEXIS, Inc. (SCYX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates